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Abstract
Blood sample processing and handling can have a significant impact on the stability and levels of proteins measured in
biomarker studies. Such pre-analytical variability needs to be well understood in the context of the different proteomics
platforms available for biomarker discovery and validation. In the present study we evaluated different types of blood
collection tubes including the BD P100 tube containing protease inhibitors as well as CTAD tubes, which prevent platelet
activation. We studied the effect of different processing protocols as well as delays in tube processing on the levels of 55
mid and high abundance plasma proteins using novel multiple-reaction monitoring-mass spectrometry (MRM-MS) assays as
well as 27 low abundance cytokines using a commercially available multiplexed bead-based immunoassay. The use of P100
tubes containing protease inhibitors only conferred proteolytic protection for 4 cytokines and only one MRM-MS-measured
peptide. Mid and high abundance proteins measured by MRM are highly stable in plasma left unprocessed for up to six
hours although platelet activation can also impact the levels of these proteins. The levels of cytokines were elevated when
tubes were centrifuged at cold temperature, while low levels were detected when samples were collected in CTAD tubes.
Delays in centrifugation also had an impact on the levels of cytokines measured depending on the type of collection tube
used. Our findings can help in the development of guidelines for blood collection and processing for proteomic biomarker
studies.
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Introduction
The detection and quantification of circulating proteins in the
blood of patients has great potential for the development of
clinically useful biomarkers. Blood has always been considered an
attractive source of biomarkers because it comes in contact with all
of the tissues in the body, and factors can be released from these
tissues into the circulation. Moreover, because blood is easily
accessible and its collection is inexpensive and minimally invasive,
it is ideal for clinical assays. Plasma and serum protein biomarkers
are already used for diagnosis, prediction, and monitoring of
response to treatment in many diseases, including cancer [1]. The
discovery of blood-based protein biomarkers is very challenging
due to the complexity of the plasma and serum proteome, and
because there is a difference of 10 orders of magnitude between
albumin and the least abundant plasma protein, which poses a
major hurdle to the discovery and validation of low-abundance
biomarkers [2]. Lately, with the development of more sensitive,
accurate and high-throughput proteomics technologies, there has
been a substantial increase in the number of candidate protein
biomarkers reported in plasma and serum from cancer patients
[3]. For instance, the use of multiple-reaction monitoring-mass
spectrometry (MRM-MS) has provided a novel and very precise
method for measuring protein biomarkers in complex tissues such
as blood, obviating the requirement for immunodepletion,
although it is still limited in sensitivity to proteins present in
nanogram/ml concentrations.
The success of any biomarker study will depend in large part on
the quality of the biospecimen analyzed, and on the control of
factors that may introduce bias to the study even before the sample
reaches the analytical platform. In the present study, we focus on
the issue of pre-analytical variability, which can be introduced at
various steps while the sample is being collected and processed,
and which has been identified as a major source of bias in
proteomics studies [4]. Some of the factors that are potential
sources of pre-analytical variation in blood clinical proteomic
studies include: the type of blood collection tube used (serum,
plasma, and use of additives), sample handling and processing,
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between sample processing and storage, and repetitive freeze/
thaw cycles of the samples [5,6].
Due to all this potential variability, standardization of protocols
for blood collection and processing is essential, especially when
sample collection takes place at multiple clinical sites [7,8].
However, a universal set of recommendations is very unlikely to be
proposed until the nature and magnitude of the variability
inherent in serum and plasma proteomics studies is fully
understood.
In order to address some of the sources of this variability (e.g.
the activation of blood proteases and platelet degranulation),
manufacturers have produced novel blood collection tubes. Our
study is an independent assessment of the impact of these tubes on
pre-analytical variability by measuring defined plasma proteins.
We analyze blood collected in tubes containing protease inhibitors,
BD
TM P100 Blood Collection Tubes, which have been developed
to stabilize proteins and minimize proteolytic degradation during
the collection and processing of blood specimens. We also analyze
blood collected in CTAD tubes, which prevent platelet degran-
ulation/activation so as to minimize the exogenous release of
proteins from platelets, which could have a significant impact on
the level of circulating plasma proteins. We assess how different
processing protocols and delays from the time of collection to
sample processing can affect the levels of low-abundance cytokines
as well as mid- to high-abundance plasma proteins. We performed
our studies using a commercially-available multiplexed bead-based
immunoassay(Bio-PlexH Suspension Array System), and, for the
first time, using a 55-protein panel on a MRM-MS platform.
Methods
Study Samples
Blood was collected from 14 fasting healthy individuals (7
females and 7 males, age range 22 to 50 years) who provided
written informed consent to participate in this study. The local
Ethics Board of the Jewish General Hospital (Montreal, Canada)
approved this study. Blood from each seated volunteer was
collected by a trained nurse. The blood was collected directly into
different blood collection tubes by a single venipuncture using the
BD VacutainerH Safety-Lok
TM Blood Collection Set (BD part #
367283). We tested three different types of blood collection tubes:
4m lk 2EDTA tubes (BD part # 366450), 8 ml k2EDTA tubes
containing protease inhibitors (BD
TM P100 Blood Collection
Tubes, BD part #366456) as well as 4.5 ml CTAD tubes (BD part
# 367947) which contain citrate as the anticoagulant and a
mixture of theophylline, adenosine, and the light-sensitive agent
dipyrimadole, which all contribute to reduce platelet activation
[9]. Each tube was filled with the required volume of blood and
gently inverted ten times to allow for appropriate mixing of
anticoagulants and tube additives. CTAD tubes were wrapped in
aluminum foil until centrifugation to protect from light. For the
time course studies, samples were immediately centrifuged (T0), or
left on the bench for 2 hrs (T2) or 6 hrs (T6) and processed
immediately thereafter. Samples were processed according to
different protocols designated A, B, C and D (Table 1). Protocol A:
samples were processed at 20006g for 5 minutes in a refrigerated
(8uC) swing-type centrifuge (initial guidelines recommended by the
manufacturer for centrifuging P100 tubes). Protocol B: samples
were swing centrifuged for 20 minutes at 25006g at room
temperature (Updated guidelines recommended by the manufac-
turer for centrifuging P100 tubes). Protocol C: samples were
processed in a swing-type centrifuge at 13006g for 10 minutes;
plasma was collected and centrifuged again in a countertop
microcentrifuge at 25006g for 15 minutes to remove any
potentially-remaining cellular material. Both centrifugations were
done at room temperature. Protocol D: samples were centrifuged
at 13006g for 10 minutes at room temperature; plasma was
collected and passed through a 0.45 mm nylon filter to remove any
potentially-remaining cellular material.
All samples collected were aliquoted in cryovials (250 ml/
2aliquot) and stored at 280uC immediately after processing. The
maximum time from the time of collection to the time of storage at
280uC was 1 hour. Samples were never thawed until immediately
before analysis to avoid any effect of freeze/thawing.
MRM Analysis
A3 - mL aliquot of each plasma sample was used to prepare
plasma tryptic digests. Samples were diluted and denatured by the
addition of 174.5 mL of 25 mM ammonium bicarbonate (AMB)
and 30 mL of 10% w/v sodium deoxycholate (NaDOC) [10].
Denatured plasma samples were reduced with 5 mM tris(2-
carboxyethyl)phosphine (TCEP) and incubated at 60uC for
30 min. Free sulfhydryl groups were alkylated with 10 mM
iodoacetamide for 30 min at 37uC in the dark. Next, 10.5 mLo f
modified porcine trypsin solution (0.4 mg/mL in 25 mM AMB,
Promega Gold Sequencing Grade) was added to each sample to
give a final digest volume of 300 mL. Samples were digested for
16 h at 37uC. Digestion was stopped by the addition of acidified
SIS peptides (Top45 SIS peptide cocktail [11] except the peptide
encoding for transferrin, plus 11 additional peptides including two
new peptides encoding for transferrin (Table S1)) in formic acid to
produce a final formic acid concentration of 0.5% v/v. Samples
were centrifuged for 5 min at 13,0006g (23uC) to remove
NaDOC precipitate, and the supernatant was desalted and
concentrated by solid phase extraction using Waters Oasis HLB
Elution plates (2 mg). The eluted samples were vacuum concen-
trated to dryness and rehydrated in a volume of Solvent A (0.1%
v/v formic acid) corresponding to a 1/70 dilution of plasma prior
to LC-MS/MS analysis. LC-MRM/MS analysis of plasma digests
was performed as previously reported [11]. Briefly, the LC-MRM-
MS system consisted of an Eksigent NanoLC-1Dplus interfaced to
an Applied Biosystems (AB)/MDS Sciex 4000 QTRAP. The MS
was equipped with a nanoelectrospray ionization source and was
controlled by AB’s Analyst 1.5 software. A reversed-phase
capillary column (75 mm615 cm) packed in house using Magic
C18AQ (5-mm diameter particles, 100-A ˚ pore size; Michrom,
Auburn, CA), was used for the on-line separations, at a flow rate of
300 nl/min. The gradient used consisted of a six minute hold at
100% solvent A (2% acetonitrile, 0.1% formic acid), followed by a
Table 1. Blood tubes and processing protocols.
Tube Protocol RCF (x g)
Time
(minutes) Temperature
P100 A 2000 5 8uC
P100 B 2500 20 RT
P100 C 1300
{ 10 RT
2500
{ 15 RT
kEDTA C 1300
{ 10 RT
2500
{ 15 RT
CTAD D 1300 10 RT
{First centrifugation.
{Second centrifugation.
doi:10.1371/journal.pone.0038290.t001
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to 43%B. The MS acquisition parameters were: positive ion mode;
ion spray voltage,1900–2000 V; curtain gas, 25 p.s.i.; interface
temperature, 200uC; collision-induced dissociation (CID) pressure,
3.5610
5 torr; and Q1 and Q3 set to unit resolution (0.6–0.8-Da
full width at half-height). MRM acquisition methods (60 min in
length) were constructed using 3 MRM ion pairs per peptide (336
MRM ion pairs total) using peptide-specific tuned Declustering
Potential and Collision Energy voltages and retention time
constraints (Table S2). A default collision cell exit potential of
23 V was used for all MRM ion pairs, and the scheduled MRM
option was used for all data acquisition with a target cycle time of
1 second and a 5 min MRM detection window. Blank solvent
injections (30 min analyses) were analyzed between all patient
samples to prevent sample carryover on the HPLC column.
MRM Data Analysis
We used a concentration balanced SIS-peptide mixture to
normalize peak areas against the peak areas of co-eluting SIS
peptides [11]. All MRM data was processed using MultiQuant
TM
Software Version 1.1 (Applied Biosystems) with the MQL
algorithm for peak integration. A 2-min retention-time window,
with ‘‘report largest peak’’ enabled and a 1-point Savitsky-Golay
smooth with a peak-splitting factor of 2, was used. The default
MultiQuant
TM values for noise percentage and baseline subtrac-
tion window were used. All data was manually inspected to ensure
correct peak detection and accurate integration. Linear regression
of all calibration curves was performed using a standard 1/6
(x=concentration ratio) weighting option to aid in covering a wide
dynamic range.
Cytokine Bio-Plex Assay
We used the Bio-PlexH Suspension Array System (Bio-Rad,
CA), a bead based multiplex immunoassay [12], and the 27-plex
human cytokine panel (Bio-Rad part # M50-0KCAF0Y) to
measure the levels of IL-1b, IL-1 receptor antagonist (IL-1RA), IL-
2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-
15, IL-17, Eotaxin, FGF-b, granulocyte colony-stimulating factor
(G-CSF), GM-CSF, interferon (IFN)-c, IP-10, monocyte chemoat-
tractant protein (MCP)-1, macrophage inflammatory protein
(MIP)-1a, MIP-1b, platelet-derived growth factor BB (PDGF-
BB),regulated on activation normal T-cell expressed and secreted
(RANTES), tumour necrosis factor (TNF), and vascular endothe-
lial growth factor (VEGF). Whole plasma was diluted 46 in
human serum diluent, and the assay was performed according to
the manufacturer’s guidelines. Samples were measured in dupli-
cate and read with the LuminexH 200
TM system (Bio-Rad
Laboratories, Hercules, CA). Data was analysed using Bio-Plex
Manager
TM Software Version 4.0 (Bio-Rad, CA). The calibration
curve for each cytokine was analysed with both 4PL and 5PL
logistic regression curves and the best fit curve was chosen for
further analyses. Data was considered reliable if at least 5 data
points from the calibration curve fell within 70–130% of the
expected values as recommended by the manufacturer. Two
separate Bio-PlexH runs were performed. By applying the above
criteria, we could reliably measure 21 cytokines and 20 cytokines
in the first and second Bio-PlexH experiments, respectively.
Statistical Analyses
For statistical purposes, cytokines that were below the level of
detection of the Bio-PlexH assay were assigned an arbitrary value
corresponding to half of the limit of detection (LOD) of the
analyte. We used two-tailed paired t tests to make comparisons
between tube types and between time points. One-Way ANOVA
repeated measures and Tukeys Post-hoc method [13] was used for
the time-course analyses. All statistical analyses were done with
GraphPad Prism Version 5 (San Diego, CA).
Results
Effect of Collection Tube and Delays in Processing of
Blood Sample on Mid– to High Abundance Plasma
Proteins as Determined by MRM
To study the effect of blood collection tube and delays in
processing on the measurement of medium to high abundance
plasma proteins, we used multiple reaction monitoring (MRM)
and stable isotope-labeled standard peptides. With this approach,
we were able to measure plasma levels of 55 mid- to high-
abundance plasma proteins. For this assay, we analysed plasma
collected in P100 tubes, k2EDTA tubes and CTAD tubes all
processed with comparable protocols (C and D) (Table 1). We also
performed a time-course study and samples were processed at time
0, 2 hours or 6 hours following collection. The reproducibility of
each individual MRM assay was assessed and the %CV for all the
peptides was below 20% with 51 peptides having %CVs below
10% (Table S1).
With MRM-MS, we could not identify any differences in the
levels of tryptic peptides measured in plasma collected in k2EDTA
tubes with (P100 tubes) or without protease inhibitors at any of the
time points analysed. In fact, only one peptide, proteotypic for
plasminogen, showed statistically higher levels at the 6 h time
point in k2EDTA relative to P100, but the percent difference in
concentration was minimal (only 4%) (Table 2). In contrast, blood
collection in CTAD tubes resulted in significant differences in the
levels of peptides measured when compared to the other collection
tubes used. The most common finding was significantly lower
(p,0.05) levels of peptides in samples collected in CTAD tubes. Of
the 56 peptides analysed, lower levels were observed for 21
peptides in samples processed at time 0, 28 peptides in samples
processed at time 2 h, and 41 peptides in samples processed at
time 6 h; in CTAD tubes compared to all other tube types
(Table 3). Of the 21 peptides with lower levels at time 0 in CTAD
tubes, the levels of 7 were lower relative to both P100 and
k2EDTA tubes; the levels of 8 were lower relative to k2EDTA
tubes only and the levels of 6 were lower relative to P100 tubes
only (the percent decreases ranged from 10%–48%). Of the 28
peptides with lower levels in CTAD samples processed at time 2
hours, 7 presented lower levels in CTAD samples relative to both
P100 and k2EDTA tubes and the levels of 21 peptides were lower
in CTAD tubes relative to P100 tubes only (the percent decreases
ranged from 11%–45%). Finally, of the 41 peptides with lower
levels in CTAD samples processed at time 6 h, 16 had lower levels
relative to both P100 and k2EDTA samples, 4 were lower in
CTAD relative to k2EDTA only and 21 were lower in CTAD
relative to P100 tubes only (the percent decreases ranged from
9%–47%) (Table 3).
The lower levels of many of these peptides in plasma from
CTAD tubes suggest that platelet activation may be involved in
the release of several of these mid- to high- abundance proteins
during delayed sample processing, consistent with previous studies
reporting the presence of many of the analysed proteins within
platelets [14]. Very few of the peptides measured showed higher
levels in samples collected in CTAD tubes. The peptide encoding
for fibronectin was the only one with consistently higher levels in
CTAD samples at all time points, and with the highest percent
increase, ranging from 64–128% (Table 3).
The time course analysis of the MRM data revealed that the
proteotypic peptides were relatively stable over time when
Pre-Analytical Variability on Plasma Proteomics
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38290Table 2. Percent differences in peptide levels between tube types measured by MRM.
Time 0 Time 2 Time 6
P100:k-EDTA P100:k-EDTA P100:k-EDTA
Protein Peptide % % %
Adiponectin IFYNQQNHYDGSTGK 12.28 213.79 5.25
Afamin DADPDTFFAK 10.70 22.47 24.38
Albumin, serum LVNEVTEFAK 4.35 21.29 20.81
Alpha-1-acid glycoprotein 1 NWGLSVYADKPETTK 20.15 11.24 9.91
Alpha-1-antichymotrypsin EIGELYLPK 2.33 0.42 20.26
Alpha-1-Anti-trypsin ITPNLAEFAFSLYR 24.00 210.49 27.75
Alpha-1B-glycoprotein LETPDFQLFK 2.62 26.00 22.99
Alpha-2-antiplasmin LGNQEPGGQTALK 9.98 21.59 5.18
alpha-2-HS-glycoprotein HTLNQIDEVK 2.80 20.60 1.80
alpha-2-macroglobulin TEHPFTVEEFVLPK 6.51 22.50 23.71
Angiotensinogen ALQDQLVLVAAK 6.46 25.29 0.71
Antithrombin-III DDLYVSDAFHK 6.59 21.67 10.56
Apolipoprotein A-I ATEHLSTLSEK 6.53 22.44 21.68
Apolipoprotein A-II precursor SPELQAEAK 9.27 2.98 3.33
Apolipoprotein A-IV SLAPYAQDTQEK 9.23 1.02 23.01
Apolipoprotein B-100 FPEVDVLTK 1.26 23.03 22.50
Apolipoprotein C-I lipoprotein TPDVSSALDK 10.39 0.70 23.01
Apolipoprotein C-III GWVTDGFSSLK 19.42 9.11 5.62
Apolipoprotein D IPTTFENGR 25.55 24.96 26.50
Apolipoprotein E LGPLVEQGR 5.73 4.36 24.90
Apolipoprotein L1 VTEPISAESGEQVER 6.26 23.35 220.92
Beta-2-glycoprotein I ATVVYQGER 3.03 22.52 22.94
Ceruloplasmin EYTDASFTNR 6.80 22.10 210.93
Clusterin ELDESLQVAER 7.74 20.91 211.37
Coagulation factor XIIa HC VVGGLVALR 7.77 28.25 20.50
Coagulation Factor XIII (a chain) STVLTIPEIIIK 26.10 10.46 23.94
Complement C1 inactivator LLDSLPSDTR 6.04 21.15 20.60
Complement C3 TGLQEVEVK 5.50 23.33 0.41
Complement C4 beta chain VDGTLNLNLR 4.03 22.61 26.41
Complement C4 gamma chain ITQVLHFTK 6.53 23.41 23.63
Complement C9 LSPIYNLVPVK 6.81 21.30 23.11
Complement factor B EELLPAQDIK 7.34 20.36 25.34
Complement factor H SPDVINGSPISQK 10.09 5.93 2.86
Fibrinogen alpha chain GSESGIFTNTK 9.46 1.18 0.34
Fibrinogen beta chain QGFGNVATNTDGK 11.35 10.59 21.90
Fibrinogen gamma chain YEASILTHDSSIR 13.78 24.11 3.84
Fibrinopeptide A ADSGEGDFLAEGGGVR 10.86 3.36 3.37
Fibronectin VPGTSTSATLTGLTR 28.53 27.64 211.19
Gelsolin, isoform 1 TGAQELLR 7.00 25.23 23.76
Haptoglobin beta chain VGYVSGWGR 2.42 22.64 23.40
Hemopexin NFPSPVDAAFR 4.70 22.32 22.09
Heparin cofactor II TLEAQLTPR 21.88 20.14 25.56
Histidine-rich glycoprotein DGYLFQLLR 8.97 21.61 26.50
Inter-alpha-trypsin inhibitor HC AAISGENAGLVR 11.27 26.15 22.31
Kininogen-1 TVGSDTFYSFK 5.66 22.72 22.81
L-selectin AEIEYLEK 10.00 3.72 1.55
Plasma retinol-binding protein YWGVASFLQK 5.17 23.22 3.19
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significant change in the levels of peptides between any of the
time points analysed. On the other hand, for samples collected in
P100 tubes, significantly lower (p,0.05) levels were observed for a
small number of peptides as a function of time: the levels of 7
peptides decreased from time 0 to the 2-hour time point and the
levels of 5 peptides decreased from time 0 to the 6-hour time point.
The levels of cytokines vary with different collection and
processing protocols used. Our cytokine analysis was per-
formed using plasma from blood collected in k2EDTA tubes and
tubes containing k2EDTA and protease inhibitors (BD
TM P100
Blood Collection Tubes). Each type of tube was processed at
several time points after collection (T0, T2, and T6) using the
processing protocol as shown in Table 1 (Protocol A or Protocol
C). We observed that for at least 80% of the cytokines detected at
time 0, the levels were higher in samples collected in k2EDTA
tubes containing protease inhibitors (P100 tubes) and processed
with the initial manufacturer guidelines (protocol A) than in
samples collected in k2EDTA tubes processed with protocol C, a
standard protocol for processing plasma samples (Figure 1). This
observation was consistent for all time points analysed (Table S3).
Paired t-tests comparing the levels of cytokines measured in both
tube types at each of the time points showed significantly (p,0.05)
higher mean concentrations in P100 plasma relative to k2EDTA
plasma for 9 cytokines in samples analysed at T0 (mean percent
change of 533% (82%–2480%)), for 10 cytokines in T2 samples
(mean percent change of 134% (29%–324%)) and for 9 cytokines
in T6 samples (mean percent change of 151% (35%–765%)).
Interleukins 2, 8, 10 and 15 were not detected in k2EDTA samples
in at least one of the time points analysed but were detectable at all
time points in samples from P100 tubes (Figure 1 and Table S3).
Only for IP-10 were higher levels detected in k2EDTA samples
when compared to P100 at all time points.
Cytokine levels were relatively stable when sample processing
was delayed for up to 2 hours; none of the cytokines from k2EDTA
tubes showed statistically significant changes, while only two
cytokines (IL-2 and IL-13) decreased in P100 tubes (Table S4).
However, after 6 hours, the mean levels of six cytokines were
significantly (p,0.05) higher (from 13%–230%) in k2EDTA
samples relative to time 0, while the concentration of 8 cytokines
decreased as a function of time in P100 samples (Figure S1). The
magnitude of the change in these cytokines in P100 tubes was less
than that observed in k2EDTA tubes, with percent changes
ranging between 8.5–43% (Supplementary Table S4). Other
cytokines did not show statistically significant changes in levels
between the time points analysed. In samples collected in k2EDTA
tubes, interleukins 2, 8, 10, and 15 were below the limit of
detection at time 0 but consistently increased with time on the
bench and reached detectable levels at the 2-hour or 6-hour time
point. None of these changes, however, reached statistical
significance. The results of this first assay thus demonstrate that
the levels of cytokines measured largely depend on the type of
collection tube and the processing protocol used, and can change
when processing is delayed after blood collection.
Variations in the protocols to process P100 tubes
significantly impact the levels of numerous cytokines
when processed immediately (time=0). The higher levels
of cytokines observed in tubes containing protease inhibitors may
be related to the fact that different protocols were used to process
each type of tube. Therefore, in order to further evaluate P100
tubes, we analysed these tubes again, this time comparing different
processing protocols recommended by the company (Protocol A
and B), in addition to the protocol used regularly in our laboratory
for plasma processing (Protocol C) (Table 1). All samples were
processed immediately after blood collection (T0). As mentioned
above, 20 cytokines out of the 27 could be measured by the assay.
Of the three different protocols used to process P100 tubes, the
most significant impact on cytokine levels was observed when we
compared the BD initial protocol (protocol A) to the other 2
protocols, i.e., BD updated protocol (protocol B) and protocol C
(in-house protocol). As shown in Figure 2, the mean levels of 16
cytokines were higher when samples were processed with protocol
A compared to protocol B. In other words, centrifugation under
refrigerated conditions for a shorter period of time resulted in
statistically significant higher levels for 15 of these analytes (nine of
which were interleukins), with percent differences ranging between
50% and 970% (Figure 2A). Protocols B and C are quite similar as
the differences between them were mainly differences in centri-
fugation speed and the addition of a second centrifugation step,
without changing centrifugation temperature. These differences
did not significantly affect plasma cytokine levels since we found
comparable levels for all analytes measured with both methods.
No statistically significant differences were observed, except for
Table 2. Cont.
Time 0 Time 2 Time 6
P100:k-EDTA P100:k-EDTA P100:k-EDTA
Protein Peptide % % %
Plasminogen LFLEPTR 10.24 0.80 4.44*
Prothrombin ETAASLLQAGYK 13.42 20.43 8.03
Serum amyloid P-component VGEYSLYIGR 19.48 11.13 3.98
Transferrin EGYYGYTGAFR 4.68 246.05 24.18
HSTIFENLANK 6.33 70.23 21.33
Transthyretin AADDTWEPFASGK 17.32 1.05 3.47
Vitamin D-binding protein THLPEVFLSK 8.07 29.36 4.24
Vitronectin FEDGVLDPDYPR 4.53 25.85 21.99
Zinc-alpha-2-glycoprotein EIPAWVPFDPAAQITK 22.67 1.53 25.03
*p,0.05.
**p,0.001.
doi:10.1371/journal.pone.0038290.t002
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Time 0 Time 2 Time 6 Time 0 Time 2 Time 6
P100:CTAD P100:CTAD P100:CTAD k-EDTA:CTAD
k-
EDTA:CTAD k-EDTA:CTAD
Protein Peptide % % % % % %
Adiponectin IFYNQQNHYDGSTGK 233.66* 241.68* 237.65 240.92* 232.35* 240.77*
Afamin DADPDTFFAK 25.17 213.39* 213.78* 214.33 211.20 29.83*
Albumin, serum LVNEVTEFAK 29.37 215.15* 217.62* 213.14 214.04 216.95**
Alpha-1-acid glycoprotein 1 NWGLSVYADKPETTK 60.99* 42.55 46.02* 33.99 28.14 32.86
Alpha-1-antichymotrypsin EIGELYLPK 29.69 213.96 213.36 211.74* 214.32 213.14*
Alpha-1-Anti-trypsin ITPNLAEFAFSLYR 248.11** 245.23** 246.95** 245.96** 238.81** 242.49**
Alpha-1B-glycoprotein LETPDFQLFK 211.53 215.86* 215.82* 213.78 210.49 213.23
Alpha-2-antiplasmin LGNQEPGGQTALK 26.79 25.87 212.09* 215.25 24.34 216.43*
alpha-2-HS-glycoprotein HTLNQIDEVK 29.61 213.69 214.43 212.07 213.16 215.94
alpha-2-macroglobulin TEHPFTVEEFVLPK 26.94 215.10 216.08* 212.63 212.92 212.84
Angiotensinogen ALQDQLVLVAAK 24.69 222.73* 217.35* 210.48 218.42 217.94
Antithrombin-III DDLYVSDAFHK 22.47* 8.27 17.34* 14.90* 10.11 6.13
Apolipoprotein A-I ATEHLSTLSEK 29.11 216.52* 216.87* 214.68 214.43 215.45
Apolipoprotein A-II precursor SPELQAEAK 12.16* 7.45 5.61* 2.64 4.34 2.21
Apolipoprotein A-IV SLAPYAQDTQEK 210.38* 216.64* 221.48** 217.95 217.48 219.04
Apolipoprotein B-100 FPEVDVLTK 213.50 213.31* 216.38* 214.57* 210.60 214.23*
Apolipoprotein C-I lipoprotein TPDVSSALDK 27.61 213.77* 218.59** 216.30 214.37 216.07
Apolipoprotein C-III GWVTDGFSSLK 19.18* 11.87 9.70* 20.20 2.53 3.87
Apolipoprotein D IPTTFENGR 221.98* 213.35* 223.83* 217.40 28.83 218.54
Apolipoprotein E LGPLVEQGR 214.13* 213.34* 226.27** 218.78 216.96 222.47
Apolipoprotein L1 VTEPISAESGEQVER 219.13 10.28 238.92 223.90 14.10 222.76
Beta-2-glycoprotein I ATVVYQGER 27.84 216.55* 214.69* 210.55 214.39 212.11
Ceruloplasmin EYTDASFTNR 0.89 21.93 215.68* 25.53 0.17 25.33
Clusterin ELDESLQVAER 219.87* 5.43 238.56 225.62* 6.40 230.68*
Coagulation factor XIIa HC VVGGLVALR 26.27 214.88* 215.31* 213.02 27.22 214.89
Coagulation Factor XIII (a chain) STVLTIPEIIIK 211.04 22.93 22.46 25.26 212.12 221.30
Complement C1 inactivator LLDSLPSDTR 220.12* 228.38* 225.15* 224.67* 227.55* 224.69*
Complement C3 TGLQEVEVK 211.69* 218.59* 219.78* 216.30* 215.79* 220.10*
Complement C4 beta chain VDGTLNLNLR 221.82* 222.86* 230.48* 224.85 220.79 225.72
Complement C4 gamma chain ITQVLHFTK 221.63* 230.71* 228.59* 226.44 228.27 225.90
Complement C9 LSPIYNLVPVK 210.37 214.24* 216.64* 216.08* 213.11 213.96*
Complement factor B EELLPAQDIK 20.98 210.32 28.84 27.75 29.99 23.70
Complement factor H SPDVINGSPISQK 26.69 216.75 213.62 215.24 221.41 216.01*
Fibrinogen alpha chain GSESGIFTNTK 210.63 216.41* 222.91* 218.35* 217.39* 223.17*
Fibrinogen beta chain QGFGNVATNTDGK 213.17* 23.50 227.57* 222.02 212.74 226.17*
Fibrinogen gamma chain YEASILTHDSSIR 28.72 215.29* 217.34* 219.77 211.66* 220.4*
Fibrinopeptide A ADSGEGDFLAEGGGVR 211.55 212.23 218.99* 220.22* 215.09 221.63*
Fibronectin VPGTSTSATLTGLTR 112* 100.56* 103.21* 64.94* 117.15* 128.81*
Gelsolin, isoform 1 TGAQELLR 216.51 225.68 221.24* 221.98 221.58 218.16
Haptoglobin beta chain VGYVSGWGR 24.79 210.49 213.00* 27.04 28.07 29.94
Hemopexin NFPSPVDAAFR 29.48 215.83* 216.44* 213.54 213.83 214.65*
Heparin cofactor II TLEAQLTPR 210.41 217.59* 219.00* 28.69 217.47 214.24
Histidine-rich glycoprotein DGYLFQLLR 210.27 211.50* 214.33* 217.66* 210.05 28.37
Inter-alpha-trypsin inhibitor HC AAISGENAGLVR 22.22 24.77 27.60 212.13 1.47 25.41
Kininogen-1 TVGSDTFYSFK 211.63* 216.86* 217.27* 216.36* 214.53 214.88
L-selectin AEIEYLEK 4.26 213.83 24.46 25.22 216.92 25.92
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processed with Protocol C (p=0.03) (Figure 2B). Thus it appears
that results with the P100 tubes are largely dependent on the
temperature at which centrifugation of the plasma samples is
performed. Interestingly, we identified three proteins whose levels
were very stable irrespective of the P100 tube processing protocol:
these include Eotaxin, MCP-1 and MIP-1b (Figure 2).
The presence of protease inhibitors does not significantly
impact the levels of cytokines. To directly assess whether the
presence of protease inhibitors in the collection tube had an
impact on the levels of cytokines, we compared samples collected
in k2EDTA and P100 tubes processed with identical protocols, in
this case, the in-house processing protocol, which avoids cold
centrifugation (Protocol C). We found that the addition of protease
inhibitors to the blood collection tube only had a modest but
significant effect (p,0.05) on the mean levels of four of the 20
detected cytokines. The levels of IL-8, IL-9, MCP-1 and MIP-1b
were 32%, 21% 29% and 13% higher, respectively, in P100 tubes
compared to k2EDTA tubes (Figure 2). These differences are
unlikely to be clinically significant. These findings demonstrate
that the addition of protease inhibitors to plasma collection tubes
does not significantly affect the levels of the majority of plasma
cytokines when processing is performed at room temperature.
Levels for most cytokines are low or undetectable in
samples collected in CTAD tubes. In order to directly
address the role of platelet activation during processing, we also
collected plasma samples in CTAD tubes, which contain additives
to prevent platelet activation and degranulation [9,15]. In our
analysis, we found that when samples were collected in CTAD
tubes, the levels of IL-4, IL-5, IL-6, IL-7, IL-8, IL-12p70, IL-13,
IL-17 and VEGF were below the limit of detection of the present
assay in all samples analysed (Figure 2A). Of the 11 cytokines that
were measureable in CTAD samples, eight presented lower levels
than with any other tube type or protocol used (Figure 2).
RANTES and PDGF-b are the two cytokines for which the largest
differences in the levels measured were observed. The levels of
Table 3. Cont.
Time 0 Time 2 Time 6 Time 0 Time 2 Time 6
P100:CTAD P100:CTAD P100:CTAD k-EDTA:CTAD
k-
EDTA:CTAD k-EDTA:CTAD
Protein Peptide % % % % % %
Plasma retinol-binding protein YWGVASFLQK 21.64 215.30 28.95* 26.48 212.49 211.77
Plasminogen LFLEPTR 13.73* 7.38 10.00* 3.16 6.53 5.33*
Prothrombin ETAASLLQAGYK 21.05* 10.40 11.47 6.72 10.88 3.19
Serum amyloid P-component VGEYSLYIGR 34.79* 32.64 21.17 12.82 19.36 16.53
Transferrin EGYYGYTGAFR 29.64 215.46* 218.81* 213.68* 56.69 215.27*
HSTIFENLANK 28.39 214.76* 219.98* 213.84 249.93 218.90*
Transthyretin AADDTWEPFASGK 0.93 28.56 29.55* 213.97 29.51 212.59
Vitamin D-binding protein THLPEVFLSK 29.26 224.76 214.43 216.03* 216.99* 217.91
Vitronectin FEDGVLDPDYPR 26.50 214.71 217.62* 210.55 29.41 215.95*
Zinc-alpha-2-glycoprotein EIPAWVPFDPAAQITK 217.37* 27.93 217.85* 215.10* 29.32 213.50
*p,0.05.
**p,0.001.
doi:10.1371/journal.pone.0038290.t003
Figure 1. Cytokine levels at time 0. Concentration of cytokines in pg/ml from plasma collected in K2EDTA (white bars) and P100 (black bars)
tubes processed immediately after collection (T0) using protocol A. The levels of 20 cytokines detected using the Bio-PlexH Assay are shown (RANTES
levels not included in the figure, concentration is off scale). Paired t-test comparisons were performed for each cytokine between tube types. *
p,0.05, + cytokines not detected in K2EDTA samples.
doi:10.1371/journal.pone.0038290.g001
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(p=0.005) and 29.3 fold higher in K2EDTA (Protocol C) samples
(p=0.01) when compared to the levels measured in samples
collected in CTAD tubes. For RANTES, the range of fold changes
was 46.4 fold higher in P100 (Protocol A) samples (p=0.001) and
59.2 fold higher in K2EDTA (protocol C) samples (p=0.001)
compared to CTAD (Figure 2C). These findings suggest that many
of the measured cytokines may become detectable in the plasma
because of platelet activation. Interestingly, all of the cytokines that
were not detectable in the CTAD tubes were also significantly
increased in the P100 tubes when processed using Protocol A
compared with Protocol B and C, suggesting that the high levels of
these cytokines may be in part due to their release during platelet
activation resulting from cold centrifugation in protocol A.
Discussion
One of the roadblocks in biomarker research is the lack of
proper biospecimen quality assessment and quality control. As
stated by Rodriguez et al, ‘‘The first step in biomarker research
that needs to be considered is the development and improvement
of biospecimen science [16]. Careful studies on the stability of
proteins in biological matrices using different methods of
collection, processing, storage and distribution need to be carried
out’’. The impact of several pre-analytical factors on the
measurement of blood cytokines has been previously reported
[17]. However it is the first time to our knowledge that a thorough
study is performed using both a large multiplex panel (27-plex) and
the novel 55-peptide MRM-MS panel to assess the role of factors
such as novel blood collection tubes, different processing protocols
and delays to centrifugation. Although enzymatic degradation of
proteins has been shown to take place during blood collection and
processing [18,19], there has been no consensus as to the
recommendations for adding protease inhibitors to blood collec-
tion tubes when performing protein biomarker studies [7,8]. The
BD
TM P100 Blood Collection Tubes, containing a proprietary
cocktail of protease inhibitors, have been reported to inhibit the
intrinsic proteolytic degradation of plasma proteins and thus
stabilize the blood proteome during collection and processing [20].
Although these tubes may serve to minimize exogenous peptide
generation, our present results and those of others [21,22] have
shown that the use of these specialized tubes do not provide
enough stability to the plasma proteome to have a significant
impact on the levels of peptides measured with different platforms.
We measured 55 mid- to high-abundance proteins with MRM-
MS, a mass spectrometry based approach measuring peptides, and
27 cytokines with an antibody-based assay allowing the detection of
the whole proteins. In both instances, the levels of the majority of
factors measured in P100 tubes were comparable to the levels
measured in K2EDTA samples when the same processing protocol
wasused,andtheselevelsremainedcomparableevenwhensamples
were left unprocessed on the bench for up to 6 hours. To our
knowledge, this is the first report analysing the effect of protease
inhibitors on a large panel of mid/high abundance proteins by
MRM-MS and of cytokines. The results from our MRM study
showed no significant difference in peptide levels when comparing
Figure 2. Comparison of cytokine levels between tube types and processing protocols. Concentration of 20 cytokines in pg/ml from
plasma collected in K2EDTA tubes, P100 tubes processed with different protocols and CTAD tubes. All tubes were processed immediately after
collection (T0). Brackets depict groups compared using paired t-tests and for which statistical significance * p,0.05 was found.
doi:10.1371/journal.pone.0038290.g002
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are in contrast with the report from Randall et al, where five
abundant proteins, measured using MRM, showed significant
differenceswhenusingproteaseinhibitors[21].Onemayarguethat
the actual protective effect of protease inhibitors on the intact
protein is difficult to infer from the measurement of tryptic peptides
withMRM-MS.However,trypticpeptidescanbefurther degraded
by endogenous proteases, and this degradation could potentially
affect the results from MRM studies [23]. The highly comparable
levels of peptides from samples collected in P100 and K2EDTA
tubes in our MRM study suggest that such degradation may not be
noticeableatthetimepointsanalysedandthatproteaseinhibitorsdo
not confer a significant advantage over regular K22EDTA tubes for
MRM-MS studies performed on samples left unprocessed for up to
six hours. Thus, in accordance with our conclusions, the Randall
study states that the use of specialized collection tubes containing
protease inhibitors is not required for MRM assays if strict blood
processing protocols are implemented.With the significantly higher
cost of P100 tubes (,$20) vs K2EDTA (,$1), the adoption of this
blood collection method becomes less than attractive for clinical
biomarker studies, which often require the collection of a large
number of blood biospecimens.
Our comparison of protocols to process P100 tubes highlights the
importance of standardizing centrifugation conditions. The signifi-
cantly higher levels of a large number of cytokines measured in
samples processed with protocol A is likely to reflect the effect of
having a larger number of platelets present in plasma, due to the
short centrifugation, and to the release of cytokines from platelets,
due to their activation by the cold temperature. Platelets are
extremely reactive cells that respond to various stimuli to secrete
active compounds, such as cytokines, stored in specific organelles.
Shear stress and also exposure to cold temperature during
centrifugation alter the morphology of the platelet cells and can
result in the activation of a cascade of events eventually resulting in
the platelet release reaction [24,25]. This can significantly impactthe
results from biomarker studies as seen with the differences in peptide
profiles in plasma reported to be caused by the presence and
activation of platelets by exposure to low temperatures [7].
Therefore, when samples cannot be processed immediately, it is
preferable to keep them at room temperature and avoid refrigeration
or keeping them on ice prior to and during processing in order to
minimize pre-analytical variability. This is especially critical if
cytokinesarethebiomarkersofinterest,sincethelevelsmeasuredwill
more likely be the result of biospecimen handling rather than of the
disease state. Interestingly, MCP1, eotaxin and MIP-1b were found
to be very stable and comparable concentrations were detected in
samples centrifuged in the cold and at room temperature. Therefore,
the levels of these cytokines do not appear to be regulated by platelet
activation as further corroborated by their high levels detected in
CTAD plasma. Nonetheless, it is important to keep in mind that
despitethefactthatsomeproteinsmaybequitestableunderdifferent
processing conditions, the majority of cytokines is not.
One of the methods suggested to control for this ex-vivo release of
cytokines from platelet stores is the collection of blood samples in
specialized tubes to inhibit platelet activation. In fact, we found
that with the use of citrate-theophylline-adenosine-dipyrimadole
(CTAD) tubes the levels of the majority of cytokines were very low
or below the limit of detection of the Bio-PlexH assay. These results
probably reflect the inhibition of in vitro release of growth factors
from platelets by CTAD through an increase in cAMP and
blockage of calcium-mediated platelet activation as reported by
Zimmermann et al [26]. It is important to note that blood samples
were collected from healthy volunteers who likely have very low
normal levels for most of these cytokines. However in a disease
state, a large number of cytokines may reach detectable
concentrations. When measuring clinically relevant low-abun-
dance biomarkers known to be stored in platelets, for example
VEGF, the prevention of platelet activation by the use of CTAD
tubes should help minimize the variability that can arise during
blood collection and processing [27,28]. Our results show that this
is not only relevant to the measurement of low-abundance
biomarkers such as cytokines, but also to levels of mid- to high-
abundance proteins. In fact, platelets also contribute to the
circulating levels of many of these abundant plasma factors since
many of these are stored within platelet alpha granules [14,29].
Although lower levels of peptides were detected for many of these
proteins in CTAD samples when compared to K2EDTA samples,
the magnitude of the difference (8%–48% decrease) was not as
drastic as the difference observed when comparing cytokines levels
between CTAD and K2EDTA samples (4%–99% decrease).
The centrifugation of collected blood specimens is likely to be
delayed in a clinical setting, due to lack of both human and/or
technical resources. Our analysis of samples left un-processed on
the bench at room temperature for up to 6 hours showed that
there is no impact of such delays in samples that are going to be
analysed for mid- to high-abundance plasma proteins using
MRM-MS technology. However, we found that increases in the
levels of cytokines can be expected due to the release of such
factors from platelets, which were activated during centrifugation.
To obtain meaningful results from proteomic blood biomarker
studies, it is imperative to standardize all the methods for blood
collection and processing. Our recommendations follow those of
HUPO and EDRN [7,8] for the use of k22EDTA plasma for
proteomic biomarkers studies, and we find the use of tubes
containing protease inhibitors to add extra cost to biomarker
studies with little benefit to the protection and stabilization of the
blood proteome. As part of any biobanking effort or biomarker
study, we strongly recommend the collection of additional blood
samples in CTAD tubes to be used for cytokine biomarker studies
or other biomarkers likely to be present and released from
platelets. Finally, we recommend processing samples immediately
after collection and, unlike the EDRN protocol, to avoid
refrigeration or centrifugation at cold temperatures to prevent
platelet activation. As shown by de Jager et al [17] It is important
to also consider the effect of freeze-thaw cycles and long term
storage. The collection of datasheets with key information, such as
deviations to SOPs, hemolysis, aliquot freeze-and-thaw cycles and
length of storage is necessary to ensure the tracking of sample
quality and will serve as future reference in the eventuality that
results from blood biomarker studies need to be further verified.
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